Author

Tejas Patil

Observed names: Patil, T., Patil, Tejas, Patil,T., T. Patil, Tejas T. Patil

Institutions: University of Colorado Cancer Center, University of Colorado Anschutz

Observed institutions: Memorial Sloan Kettering Cancer Center, Johns Hopkins University, University of Colorado Boulder, Tata Memorial Hospital, Yale University, University of Colorado Health, University of Colorado Cancer Center, Advanced Centre for Treatment, Research and Education in Cancer, Sidney Kimmel Comprehensive Cancer Center, University of Colorado Anschutz, University of Colorado Denver

ORCID: 0000-0003-4389-1010

Observed ORCID: 0000-0003-4389-1010

OpenAlex ID: A5029516360

Non–Small Cell Lung Cancer, Version 4.2024

2024 · Gregory J. Riely, Douglas E. Wood, et al. · Journal of the National Comprehensive Cancer Network · 858

NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023

2023 · David S. Ettinger, Douglas E. Wood, et al. · Journal of the National Comprehensive Cancer Network · 498

PDF

Management of Brain Metastases in Tyrosine Kinase Inhibitor–Naïve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis

2017 · William J. Magnuson, Nataniel H. Lester-Coll, et al. · Journal of Clinical Oncology · 461

The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib

2018 · Tejas Patil, Derek E. Smith, et al. · Journal of Thoracic Oncology · 203

A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics

2024 · Danh-Tai Hoang, Gal Dinstag, et al. · Nature Cancer · 155

PDF

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

2022 · Alexander Drilon, Chao-Hua Chiu, et al. · JTO Clinical and Research Reports · 114

PDF

Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation

2021 · Nicholas J. Thomas, Nathaniel J. Myall, et al. · Journal of Thoracic Oncology · 108

PDF

NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025

2025 · Gregory J. Riely, Douglas E. Wood, et al. · Journal of the National Comprehensive Cancer Network · 83

Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer

2018 · Terry L. Ng, Yiwei Liu, et al. · Cancer · 77

PDF

ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events

2018 · Terry L. Ng, Derek E. Smith, et al. · Journal of Thoracic Oncology · 74

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

2024 · Collin M. Blakely, Anatoly Urisman, et al. · Journal of Clinical Oncology · 72

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

2024 · Luke R.G. Pike, Emily Miao, et al. · Journal of Clinical Oncology · 56

PDF

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

2022 · Xiuning Le, Christina Baik, et al. · The Oncologist · 52

PDF

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

2024 · Amin H. Nassar, So Yeon Kim, et al. · Journal of Thoracic Oncology · 46

PDF

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

2023 · Michael J. Grant, Jacqueline V. Aredo, et al. · Clinical Cancer Research · 42

PDF

Influence of genetic polymorphisms on frequency of micronucleated buccal epithelial cells in leukoplakia patients

2010 · Manoj B. Mahimkar, Tanuja A. Samant, et al. · Oral Oncology · 42

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

2021 · Natalia J. Gurule, Caroline E. McCoach, et al. · npj Precision Oncology · 41

PDF

CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.

2022 · Daniel R. Carrizosa, Mark E. Burkard, et al. · Journal of Clinical Oncology · 40

Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non–Small-Cell Lung Cancer

2019 · Tejas Patil, Rao Mushtaq, et al. · Clinical Lung Cancer · 39

Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

2025 · Gregory J. Riely, Douglas E. Wood, et al. · Journal of the National Comprehensive Cancer Network · 38

2020 Innovation-Based Optimism for Lung Cancer Outcomes

2020 · Erin L. Schenk, Tejas Patil, et al. · The Oncologist · 35

PDF

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

2021 · Noura J. Choudhury, Jaime L. Schneider, et al. · JTO Clinical and Research Reports · 33

PDF

Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology

2023 · David S. Ettinger, Douglas E. Wood, et al. · Journal of the National Comprehensive Cancer Network · 31

PDF

Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology

2026 · Gregory J. Riely, Douglas E. Wood, et al. · Journal of the National Comprehensive Cancer Network · 30

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas

2023 · Shivaani Kummar, Lin Shen, et al. · Cancer · 30

PDF

Works count: 184

Citation count: 3,802

H-index: 26

I10-index: 45